PoPo, While I appreciate the article links, I d
Post# of 5066
Posted On: 08/25/2014 10:17:14 AM
PoPo,
While I appreciate the article links, I don't think we can assume all dedentric applications will be under Regen or even associated with Regen as Dr. Min is only under contract for Regen for dCellVax and it's stated cancer goals as outlined in previous PRs. Certainly, we can hope that if Regen is successful and has a good relationship with Dr. Min, that other applications may come under contract, but these articles show how many others beyond Dr. Min are involved so we cannot assume that all new dedentric cell applications will impact Regen.
That being said, the human cell verification is significant, but it is something we had already assumed had or would occurr when given an August IND date for dCellVax. It means some progress has been made, but the continual silence in between snippet PRs that don't address the overall picture of progress and silence for over 3 months after HemaXellerate I "clarification submission" to me is a troubling sign.
I'm over invested in BMSN and yes I held to acquire REGEN dividend shares, so I have both, but having bought most back on the promising IND of HemaXellerate back in Feb/Mar of 2013, to arrive at August 2014 with no clinical trials approved for HemaXellerate, no concrete news really stating its status, issues and timeframe of resolution (if any) and now a sheepish PR on dCellVax that doesn't update timeframe or info on IND is not encouraging to me as to Koos and company being on track for real results of entering clinical trials which is what is needed for this stock to recuperate value.
I will wait and see as I do not have much choice given my current devaluation.
While I appreciate the article links, I don't think we can assume all dedentric applications will be under Regen or even associated with Regen as Dr. Min is only under contract for Regen for dCellVax and it's stated cancer goals as outlined in previous PRs. Certainly, we can hope that if Regen is successful and has a good relationship with Dr. Min, that other applications may come under contract, but these articles show how many others beyond Dr. Min are involved so we cannot assume that all new dedentric cell applications will impact Regen.
That being said, the human cell verification is significant, but it is something we had already assumed had or would occurr when given an August IND date for dCellVax. It means some progress has been made, but the continual silence in between snippet PRs that don't address the overall picture of progress and silence for over 3 months after HemaXellerate I "clarification submission" to me is a troubling sign.
I'm over invested in BMSN and yes I held to acquire REGEN dividend shares, so I have both, but having bought most back on the promising IND of HemaXellerate back in Feb/Mar of 2013, to arrive at August 2014 with no clinical trials approved for HemaXellerate, no concrete news really stating its status, issues and timeframe of resolution (if any) and now a sheepish PR on dCellVax that doesn't update timeframe or info on IND is not encouraging to me as to Koos and company being on track for real results of entering clinical trials which is what is needed for this stock to recuperate value.
I will wait and see as I do not have much choice given my current devaluation.
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼